Transatlantic firm boosts finance, litigation, environmental and tax bench with hires from rivals including Eversheds Sutherland and PwC
Chad Ho is replacing long-time legal chief Stacey Goff, who is exiting after 26 years with the company
Aymen Mahmoud to replace Hamid Yunis as London managing partner, with Graham White named senior partner
M&A partner Maria-Leticia Ossa Daza joins in New York having founded and led Willkie’s LatAm practice
Partners Tom Tippetts, Brandon McCoy and Chase Proctor join from Texan firm as four Willkie private equity partners relocate
Led by respected life sciences litigator Siegmund Gutman, the team of 10 move over from Proskauer Rose
Luke McDougall joins as Wall Street firm moves to build out UK leveraged finance bench
Jeff Novota will replace Mark Shaw, who is moving to an advisor role after almost 24 years as CLO
Former Australian prime minister and UK secretary general will discuss state-related dispute resolution at June event
US firm will continue to operate in Hong Kong, but bulk of office will resurrect historic Johnson Stokes & Master brand
Announcement of former Shearman tax partner’s arrival came on day A&O Shearman came into being
Düsseldorf local division orders US life sciences company Curio Bioscience to stop selling its products in Germany, France and Sweden in dispute with rival 10x Genomics
David Weintraub will replace Michael Solender at the Big Four firm in July
Group includes 13 partners including Frank Segall and Josef Volman, who will co-chair new office
Kenneth Burdon to be joined by Simpson Thacher funds partner Nathan Somogie for launch later this year
Four hundred-strong practice brings together alternative legal services and tech teams
Transatlantic merger creates global giant with nearly 4,000 lawyers and $3.5bn revenue
UK pharmaceutical firm enters the fray in the battle over mRNA technology used to develop blockbuster vaccines
Nikkei Asia reports that Hong Kong lawyers will revive historic Johnson Stokes & Master brand
Greenberg counsels Ono in deal to expand Japanese group’s oncology portfolio and US presence